The Effects on the Femoral Cortex of a 24 Month Treatment Compared to an 18 Month Treatment with Teriparatide: A Multi-Trial Retrospective Analysis

Teriparatide (TPTD) is an anabolic agent indicated for the treatment of severely osteoporotic patients who are at high risk of fragility fractures. The originally approved duration of TPTD treatment in several regions, including Europe, was 18 months. However, studies of areal bone mineral density (...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2016-02, Vol.11 (2), p.e0147722-e0147722
Hauptverfasser:	Whitmarsh, Tristan, Treece, Graham M, Gee, Andrew H, Poole, Kenneth E S
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Aged Analysis Biocompatibility Biology and Life Sciences Biomedical materials Bone density Bone Density - drug effects Bone mineral density Care and treatment Clinical trials Complications and side effects Computed tomography Cortical bone Datasets Dosage and administration Drug therapy Female Femur Femur - drug effects Femur - pathology Femur - physiopathology Fractures Fragility Hip Hormone replacement therapy Humans Medical research Medicine and Health Sciences Middle Aged Osteoporosis Osteoporosis - drug therapy Osteoporosis - pathology Osteoporosis - physiopathology Parathyroid hormone Patient outcomes Patients Physical Sciences Physiological aspects Research and Analysis Methods Studies Surgical implants Teriparatide Teriparatide - pharmacology Teriparatide - therapeutic use Time Factors Visual cortex
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!